Genedy Rasha Mahmoud, Owais Marwa, El Sayed Naglaa Mohamed
Dermatology, Venereology, and Andrology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt.
Dermatol Pract Concept. 2025 Jan 30;15(1):4737. doi: 10.5826/dpc.1501a4737.
Kaposi sarcoma (KS) is a low grade angio-proliferative tumor of endothelial origin. Human herpesvirus 8 (HHV8) plays a major role in the pathogenesis of KS. Classic Kaposi sarcoma is commonly seen among elderly of Mediterranean origin. It is usually slowly progressive and is rarely fatal. There is no definitive cure for KS. Beta blockers were used with great success in the treatment of infantile hemangioma. Because of some similarity between infantile hemangioma and KS, topical beta blockers were tried with variable success rate.
We aimed to assess the efficacy and safety of oral propranolol in the treatment of classic KS.
Fifteen patients diagnosed with classic KS were prospectively enrolled in the study. Detailed history and full clinical examination were conducted. Histopathological diagnosis with confirmatory immune staining was done for all patients. Oral propranolol in a dose of 60 mg was given per day for 6 months. The patients assessed clinically as complete responders, partial responders, and non-responders.
Nine patients (60%) were partial responders; showed 50% reduction in the number of the existing lesions, and 6 patients (40%) were considered non-responders; 3 with stable disease and 3 with progressive disease. Lymphedema partially improved in 1 patient.
Oral propranolol is a safe and good option for treatment of patients with non-complicated classic KS, especially elderly with multiple comorbidities.
卡波西肉瘤（KS）是一种起源于内皮细胞的低度血管增殖性肿瘤。人类疱疹病毒8（HHV8）在KS的发病机制中起主要作用。经典型卡波西肉瘤常见于地中海地区的老年人。它通常进展缓慢，很少致命。KS尚无确切的治愈方法。β受体阻滞剂在婴儿血管瘤的治疗中取得了巨大成功。由于婴儿血管瘤与KS存在一些相似之处，局部应用β受体阻滞剂的成功率各不相同。
我们旨在评估口服普萘洛尔治疗经典型KS的疗效和安全性。
15例诊断为经典型KS的患者前瞻性纳入本研究。进行了详细的病史询问和全面的临床检查。所有患者均进行了组织病理学诊断及免疫染色确诊。口服普萘洛尔，剂量为每天60mg，持续6个月。对患者进行临床评估，分为完全缓解者、部分缓解者和无反应者。
9例患者（60%）为部分缓解者，现有病灶数量减少50%；6例患者（40%）被认为无反应，其中3例病情稳定，3例病情进展。1例患者的淋巴水肿部分改善。
口服普萘洛尔是治疗无并发症的经典型KS患者的安全且良好的选择，尤其是患有多种合并症的老年人。
